Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.49 |
| ▸ | GRM5 | P41594 | 10/20 | 0.49 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 4/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24753346 | 0.89 | GRM1 (0.48) | GRM1GRM5PDK4CDK9NAMPT | |
| SCHEMBL30120328 | 0.89 | GRM1 (0.48) | GRM1GRM5PDK4CDK9NAMPT | |
| SCHEMBL4542408 | 0.84 | GRM1 (0.56) | GRM1GRM5PDK4CDK9NAMPT | |
| SCHEMBL4539597 | 0.83 | PDK4 (0.48) | GRM1GRM5PDK4CDK9NAMPT | |
| SCHEMBL25175444 | 0.82 | PDK4 (0.53) | GRM1GRM5PDK4CDK9NAMPT | |
| SCHEMBL12895283 | 0.82 | GRM1 (0.54) | GRM1GRM5PDK4CDK9NAMPT | |
| SCHEMBL3435563 | 0.82 | GRM1 (0.47) | GRM1GRM5PDK4CDK9NAMPT | |
| SCHEMBL31131369 | 0.81 | PDK4 (0.52) | GRM1GRM5PDK4CDK9NAMPT | |
| SCHEMBL6396667 | 0.81 | PDK4 (0.52) | GRM1GRM5PDK4CDK9NAMPT | |
| SCHEMBL23216352 | 0.81 | GRM1 (0.50) | GRM1GRM5PDK4NAMPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| WO-2012062752-A1 | RADIOLABELLED mGLuR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | GRM2, GRM3, GRM1 | GRM1 3/4885GRM5 6/4885PDK4 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.